Half-Billion-Dollar Investment Lonza to Build Large-Scale Fill & Finish Facility for Commercial Drug Products

Source: Press release MA Alexander Stark

Related Vendors

Manufacturing company Lonza announced plans to establish a new large-scale, commercial drug product fill and finish facility to support customers across the entire product life cycle. The company will invest approximately 520 million dollars in the facility.

Lonza wants to establish a large-scale, commercial drug product Fill & Finish Facility in Stein, Switzerland.(Source:  Lonza)
Lonza wants to establish a large-scale, commercial drug product Fill & Finish Facility in Stein, Switzerland.
(Source: Lonza)

The global development and manufacturing partner to the pharma, biotech and nutrition industries, Lonza, announced plans to construct a large-scale commercial drug product fill and finish facility in Stein, Switzerland.

The investment will enable the company to provide customers with a complete and integrated end-to-end solution that includes commercial drug product manufacturing for large-scale market supply. The new facility will be delivered through an investment of approximately 520 million dollars and is expected to be completed in 2026.

Since establishing drug product development and manufacturing services in 2016, the manufacturer has expanded its clinical drug product offering in Basel, Stein and Visp (Switzerland), and Guangzhou (China).

The new flexible facility will be constructed in Stein on the same campus as Lonza’s current clinical drug product facility, allowing the company to leverage the existing infrastructure, capabilities and talent.

According to the company, the facility will embrace the latest developments in sustainable construction, taking a modern approach to carbon reduction and responsible energy use, including the installation of a photovoltaic roof.

(ID:48445873)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Unfold for details of your consent